Chimeric Antigen Receptor-Natural Killer Cells: The Future of Cancer Immunotherapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed.

1. Single-chain variable fragment affinity tuning can optimize anti-AML CAR-NK cell functionality.Journal for immunotherapy of cancer · 2025
   Article
2. Novel strategies to overcome tumor immunotherapy resistance using CAR NK cells.Frontiers in immunology · 2025
   Review
3. Prospects for γδ T cells and chimeric antigen receptor γδ T cells in cancer immunotherapy.Frontiers in immunology · 2025
   Review
4. Novel strategies in Parkinson's disease treatment: a review.Frontiers in molecular neuroscience · 2024
   Review
5. Chimeric Antigen Receptor-T Cell and Oncolytic Viral Therapies for Gastric Cancer and Peritoneal Carcinomatosis of Gastric Origin: Path to Improving Combination Strategies.Cancers · 2023
   Review
6. Haematopoietic cell-derived exosomes in cancer development and therapeutics: From basic science to clinical practice.Clinical and translational medicine · 2023
   Review
7. The application, safety, and future ofBioImpacts : BI · 2023
   Review
8. Radiation for hematologic malignancies: from cell killing to immune cell priming.Frontiers in oncology · 2023
   Review
9. CAR-NK as a Rapidly Developed and Efficient Immunotherapeutic Strategy against Cancer.Cancers · 2022
   Review
10. Advancing therapy for osteosarcoma.Nature reviews. Clinical oncology · 2021
    Review
11. Future trends in synthetic biology in Asia.Advanced genetics (Hoboken, N.J.) · 2021
    Article
12. Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy.Signal transduction and targeted therapy · 2020
    Review
13. Natural Killer Cells in Immunotherapy: Are We Nearly There?Cancers · 2020
    Review
14. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.Annals of hematology · 2020
    Review
15. Innovative CAR-T Cell Therapy for Solid Tumor; Current Duel between CAR-T Spear and Tumor Shield.Cancers · 2020
    Review
16. CAR T Cell Therapy for Pediatric Brain Tumors.Frontiers in oncology · 2020
    Review
17. Cytokine Release Syndrome After Modified CAR-NK Therapy in an Advanced Non-small Cell Lung Cancer Patient: A Case Report.Cell transplantation
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.